Halladay Benjamin
SEC insider (Form 3/4/5 filer). CIK 0001953943. Chief Financial Officer at ACHIEVE LIFE SCIENCES, INC. (ACHV) and 1 other issuer. 16 reported Form 4/5 transactions since Sep 2024; latest on Oct 5, 2026. Located in BOTHELL, WA.
Companies Halladay Benjamin has filed insider reports for
- ACHIEVE LIFE SCIENCES, INC. (ACHV): Officer, Chief Financial Officer
- Esperion Therapeutics, Inc. (ESPR): Officer, Chief Financial Officer
Halladay Benjamin
CIK: 0001953943
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Oct 5, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
AwardDirectRestricted Stock Unit (RSU)
200K shares- - Oct 5, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
AwardDirectStock Option (right to buy)
200K shares- - Jul 13, 2026ESPR
Esperion Therapeutics, Inc.
DispositionDirect705.4K shares- - Jun 17, 2026ESPR
Esperion Therapeutics, Inc.
SaleDirect10.8K shares at avg. $3.15$34K - Mar 17, 2026ESPR
Esperion Therapeutics, Inc.
SaleDirect6.4K shares at avg. $2.71$17K - Mar 13, 2026ESPR
Esperion Therapeutics, Inc.
AwardDirect247.4K shares- - Dec 17, 2025ESPR
Esperion Therapeutics, Inc.
SaleDirect7.3K shares at avg. $3.67$27K - Sep 17, 2025ESPR
Esperion Therapeutics, Inc.
SaleDirect7K shares at avg. $2.81$20K - Jul 17, 2025ESPR
Esperion Therapeutics, Inc.
SaleDirect11 shares at avg. $1.11$12.265 - Jun 17, 2025ESPR
Esperion Therapeutics, Inc.
SaleDirect7.2K shares at avg. $1.15$8K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 5, 2026 |  ACHV ACHIEVE LIFE SCIENCES, INC. | Award Restricted Stock Unit (RSU) | 200,000 | - | - | Direct |
| Oct 5, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award Stock Option (right to buy) | 200,000 | - | - | Direct |
| Jul 13, 2026 |  ESPR Esperion Therapeutics, Inc. | Disposition | 705,410 | - | $0 | Direct |
| Jun 17, 2026 | ESPR Esperion Therapeutics, Inc. | Sale | 10,773 | $3.15 | $33,989 | Direct |
| Mar 17, 2026 | ESPR Esperion Therapeutics, Inc. | Sale | 6,424 | $2.71 | $17,377 | Direct |
| Mar 13, 2026 | ESPR Esperion Therapeutics, Inc. | Award | 247,430 | - | $0 | Direct |
| Dec 17, 2025 | ESPR Esperion Therapeutics, Inc. | Sale | 7,337 | $3.67 | $26,905 | Direct |
| Sep 17, 2025 | ESPR Esperion Therapeutics, Inc. | Sale | 7,046 | $2.81 | $19,785 | Direct |
| Jul 17, 2025 | ESPR Esperion Therapeutics, Inc. | Sale | 11 | $1.11 | $12 | Direct |
| Jun 17, 2025 | ESPR Esperion Therapeutics, Inc. | Sale | 7,229 | $1.15 | $8,328 | Direct |
1-10 of 16 transactions